INHBA Inhibitory Nucleic Acids for Activin A Suppression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Activin A, a cytokine involved in tissue homeostasis and cancer progression, is exploited by cancer cells for growth advantage, contributing to conditions like cancer-associated cachexia and tumor suppression, necessitating effective inhibitors to regulate its activity.
Innovation Solution
Inhibitory nucleic acid molecules, such as antisense oligonucleotides, siRNA, and shRNA, targeting Inhibin βA (inhba) sequences, are developed to reduce inhba expression and activity, thereby inhibiting activin A production.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If activin A is used to promote tissue homeostasis and organ development, then tissue repair and regeneration are improved, but cancer cell growth and tumor progression are worsened
Solution Approach 1:
The patent applies local quality by developing activin A inhibitors that specifically target cancer cells and tumor microenvironments while preserving activin A's beneficial effects in normal tissue homeostasis. The inhibitors are designed to act locally at the tumor site, distinguishing between pathological and physiological contexts of activin A signaling.
Solution Approach 2:
The patent introduces activin A inhibitors as intermediary substances that mediate between activin A's dual roles. These inhibitors selectively block activin A's harmful effects on cancer cells while allowing its beneficial effects on normal tissue regeneration to continue, effectively decoupling the opposing effects of the same cytokine.
2Object-generated harmful factors
If activin A signaling is enhanced for tumor suppression, then cancer progression is inhibited, but tissue regeneration and organ development are worsened
Solution Approach 1:
The inhibitors are designed to exert their suppressive effect locally at the tumor site rather than systemically, preserving activin A's role in normal tissue homeostasis and regeneration while blocking its tumor-promoting effects. This spatially selective inhibition resolves the contradiction between tumor suppression and tissue stability.
3Quantity of substance
If inhibitory nucleic acid molecules are used to reduce inhba expression, then activin A production is inhibited, but off-target effects and toxicity may increase
Solution Approach 1:
The patent employs parameter changes by modifying the chemical structure of the inhibitory nucleic acid molecules, including using modified nucleotides, altered backbone structures, and optimized sequence composition. These parameter modifications enhance the specificity and stability of the inhibitors while reducing off-target effects and improving pharmacokinetic properties.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The inhibitors effectively reduce inhba expression by at least 5% to 100%, offering therapeutic benefits in treating cancers, autoimmune diseases, fibrotic disorders, blood disorders, allergies, heart failure, neurodegenerative diseases, and inflammatory diseases, including pancreatic ductal adenocarcinoma and cachexia.
Implementation Method 1
Inhibitory nucleic acid molecules, such as antisense oligonucleotides, siRNA, and shRNA, targeting Inhibin betaA (inhba) sequences
Data Source
AI summary
Inhibitory nucleic acid molecules are provided as well as methods of use thereof. Specifically, the disclose provides an Inhibin BetaA (inhba) inhibitory nucleic acid molecule, which is an antisense oligonucleotide, siRNA, or shRNA. Further disclosed are sequences that are targeted by the inhba inhibitory nucleic acid molecule; and methods of treating a disease or disorder in a subject comprising administering an inhba inhibitory nucleic acid molecule to the subject, wherein the disease or disorder is selected from the group consisting of cancers, autoimmune diseases, fibrotic disorders, blood disorders, allergies and allergic diseases, heart failure, neurodegenerative diseases, cachexia and inflammatory diseases.